Palexia Sr Range 50 mg. 100 mg. 150 mg. 200 mg. 250 mg Prolonged release tablets
PDF Leaflet Revision Date: 25 October 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Management of moderate to severe chronic pain unresponsive to non-narcotic analgesia.
Dosage (summary)
Initial: 50 mg twice daily; titrate as needed, max 500 mg/day.
Special Populations
- Renal impairment
- Hepatic impairment
- Elderly patients
Pregnancy & Breastfeeding
Contraindicated in pregnancy and lactation; may cause neonatal withdrawal syndrome.
Key Drug Interactions
- Serotonergic drugs (risk of serotonin syndrome)
- CNS depressants (additive effects)
- MAO inhibitors (contraindicated)
Contraindications
- Hypersensitivity to tapentadol
- Respiratory depression
- Severe renal impairment
- Severe hepatic impairment
- Acute pancreatitis
Common side effects
- Nausea
- Dizziness
- Constipation
- Headache
- Somnolence
Counselling Points
- Take whole with liquid, may take with or without food.
- Monitor for signs of abuse or addiction.
- Caution when driving or operating machinery.
Serious warnings
- Potential for abuse and addiction
- Respiratory depression risk
- Seizure risk in susceptible patients
Important Disclaimer
The Palexia Sr Range 50 mg. 100 mg. 150 mg. 200 mg. 250 mg Prolonged release tablets professional information leaflet below is the property of Janssen Pharmaceutica and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
